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Abstract
Background: Vancomycin-resistant Enterococcus faecium (VRE) is a leading cause of hospital-acquired infections.
New, presumably better-adapted strains of VRE appear unpredictably; it is uncertain how they spread despite
improved infection control. We aimed to investigate the relatedness of a novel sequence type (ST) of vanB E.
faecium - ST796 - very near its time of origin from hospitals in three Australian states and New Zealand.
Methods: Following near-simultaneous outbreaks of ST796 in multiple institutions, we gathered then tested
colonization and bloodstream infection isolates’ antimicrobial resistance (AMR) phenotypes, and phylogenomic
relationships using whole genome sequencing (WGS). Patient meta-data was explored to trace the spread of
ST796.
Results: A novel clone of vanB E. faecium (ST796) was first detected at one Australian hospital in late 2011, then
in two New Zealand hospitals linked by inter-hospital transfers from separate Melbourne hospitals. ST796 also
appeared in hospitals in South Australia and New South Wales and was responsible for at least one major
colonization outbreak in a Neonatal Intensive Care Unit without identifiable links between centers. No exceptional
AMR was detected in the isolates. While WGS analysis showed very limited diversity at the core genome, consistent
with recent emergence of the clone, clustering by institution was observed.
Conclusions: Evolution of new E. faecium clones, followed by recognized or unrecognized movement of colonized
individuals then rapid intra-institutional cross-transmission best explain the multi-center, multistate and international
outbreak we observed.
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Background
Enterococcus faecium has become a major cause of
healthcare-associated bloodstream infections (BSI) world-
wide [1, 2]. It is often postulated that antibiotic resistance
mechanisms in E. faecium explain this success in
hospitals. However, molecular typing has now defined
clear lineages of hospital-associated E. faecium strains,
nearly all of which belong to clade A1 (also defined as
multi-locus sequence type [MLST] clonal complex 17),
that are distinct from animal and non-hospitalized human
commensal E. faecium [3–6]. Some researchers argue that
hospital-adapted E. faecium is sufficiently different to
qualify as a separate species [7].
Vancomycin-resistant enterococcus (VRE) was first
detected in Australasia in 1994, as vanA E. faecium in a
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Health in Melbourne [8]. For the next 10 years, VRE
colonization and infection remained uncommon in
Australia and New Zealand. From 2005, several geograph-
ically separate hospitals in Australia noted increasing
numbers of VRE colonized patients and VRE BSI caused
by E. faecium. In contrast to the United States and Europe,
these VRE have predominantly been vanB E. faecium, a
phenomenon that may relate to vanB carriage within
bowel anaerobes in the healthy population [9–11]. It was
assumed that the sudden increase in detection was due to
failures in infection control and cross transmission of
existing endemic VRE clones. However, a detailed
outbreak investigation at Austin Health documented the
arrival in 2005 of a new sequence type of E. faecium,
ST203 [12], initially as vancomycin-susceptible E. faecium
(VSE), with subsequent acquisition of vanB determinants
on multiple separate occasions in several distinct clones of
ST203 VSE [13]. Results from national surveys demon-
strated a similar sequence of events in other hospitals so
that by 2011, ST203 VSE and VRE had become the most
common cause of E. faecium BSI in hospitals across all
Australian states [14]. Notably, in New Zealand VRE
colonization and infection remained very uncommon.
Improved cleaning protocols were introduced at
Austin Health following the ST203 VRE outbreak, which
reduced the incidence of VRE BSI between 2009 and
2011 [15]. However despite ongoing enhanced cleaning,
we once again observed an abrupt increase in vanB VRE
E. faecium BSI from 2012 onwards that was caused by a
novel ST – we lodged the alleles with the MLST
Database (https://pubmlst.org/efaecium) and received
the designation ST796 in September 2012 [16]. Although
unknown prior to 2011, by 2013 vanB ST796 E. faecium
had caused a large outbreak of colonization in a
Melbourne Neonatal Intensive Care Unit (NICU) [17],
and by 2014 was responsible for 66% of E. faecium VRE
BSI in five separate Melbourne hospitals, largely
replacing its ST203 predecessor [18].
To investigate the emergence of ST796 we established
a multi-institutional working group to study the early his-
tory of ST796 E. faecium by whole genome sequencing
(WGS). Our principal research question was whether this
near-simultaneous multi-institution outbreak was best
explained by repeated introductions from unrecognised
VSE followed by independent acquisition of vanB, VRE
community colonization, or by VRE cross-transmission in
and between affected hospitals. We now describe the clin-
ical impact, antibiotic resistance and phylogenetic related-
ness of this newly emerged E. faecium.
Methods
Working group participants from eastern Australia and
northern New Zealand contributed ST796 E. faecium
isolates from their local outbreaks – Fig. 1 shows the
geographic distribution and number of isolates per
institution. Initial identification of E. faecium was per-
formed by the source hospital microbiology laboratory.
Most isolates were originally classified as likely ST796 by
Single Nucleotide Polymorphism High Resolution Melt
(SNP HRM – in short, a rapid typing system based on
the melt curves of common SNPs with variable G + C
content) after referral to Austin Health [19]. Subsequently,
speciation was re-confirmed by MALDI-TOF mass
spectrometry or Vitek® 2 and the vancomycin resistance
genotype determined by PCR as previously described [20].
A summary of the isolates with their epidemiological and
meta-data is provided in Additional file 1: Table S1 and
described in outline below.
Rates of Enterococcus faecium bacteremia at Austin health
Using discharge data collected by Austin Health’s infor-
mation management system, rates of VRE E. faecium
bacteremia by ST over 6-month periods per 1000
discharged patients were calculated from 2011 to 2014.
These were compared with previously published rates
from 1998 to 2010 [12].
Antibiotic susceptibility testing
Antibiotic susceptibility testing was performed on all
Austin Health, Alfred Health and John Hunter Hospital
ST796 E. faecium blood culture isolates using the Vitek®
2 and Gram Positive Susceptibility card, AST-P612, ac-
cording to the manufacturer’s instructions (bioMérieux).
Austin Health isolates were further assessed by Etest® ac-
cording to the manufacturer’s instructions (bioMérieux)
for susceptibility to streptomycin, daptomycin, tigecycline,
quinupristin-dalfopristin and chloramphenicol. Minimum
Inhibitory Concentrations (MICs) were interpreted ac-
cording to the Clinical and Laboratory Standards Institute
(CLSI) guidelines where applicable.
Provenance of 131 Enterococcus faecium isolates that
underwent WGS
Alfred Health
Alfred Health, a university teaching hospital in
Melbourne with solid organ and allogeneic bone marrow
transplantation units, experienced a marked increase
in VRE BSI in 2014; 17 consecutive VRE BSI isolates
(all E. faecium) were investigated as the STs and re-
latedness of isolates were unknown. Sixteen isolates
were found to be ST796 (the other was ST203). One
BSI isolate from 2013 identified retrospectively via
SNP HRM typing as likely to be ST796 was included
in the analysis [21].
Auckland City Hospital
Thirteen isolates were referred from Auckland City
Hospital, New Zealand, during a VRE colonization
Mahony et al. Antimicrobial Resistance and Infection Control  (2018) 7:44 Page 2 of 9
outbreak that affected more than 50 hospitalized pa-
tients in 2012. The outbreak appeared to be clonal by
pulsed field gel electrophoresis (PFGE, data not shown)
performed at the national reference laboratory (ESR,
Wellington, New Zealand), and followed the repatri-
ation in 2012 from Monash Health in Melbourne of a
patient who had been hospitalized while travelling in
Australia and acquired VRE prior to transfer. This
patient was found to have two PFGE pulsotypes of
colonizing VRE E. faecium, detected serendipitously
on antibiotic susceptibility testing, with a double zone
of inhibition observed around a streptomycin disc;
one matched the outbreak ST796 by MLST, whereas
the other pulsotype was ST203. The patient’s earlier
rectal colonization and liver abscess VRE E. faecium
isolates from Monash Health were identified as
ST203.
A single colonizing isolate from a patient in another
Auckland hospital, with no known links to Auckland
City Hospital, also typed as ST796 by MLST so was
included in WGS; this patient had similarly been
transferred from a Melbourne hospital in 2012.
Austin Health
To capture the first appearance of ST796 in Austin BSI
cases and to monitor its incidence compared to other
STs over time, 79 consecutive E. faecium isolates
obtained from all episodes of BSI at Austin Health from
1st January 2011 to 31st December 2014 were assessed.
Thirty-nine were vanB VRE, and 24 of these ST796.
Three additional isolates from early 2015 were subse-
quently identified as ST796, so were included in pheno-
typic and phlyogenomic analyses. Additionally, 32
colonizing isolates of E. faecium over the same period
obtained from high-risk patients who are routinely
screened for VRE rectal colonization, and one environ-
mental isolate detected on surveillance, with matching
SNP HRM genotype to the first ST796 BSI isolate, were
included – one VSE, 30 vanB, one vanA and one with
both vanA and vanB.
John Hunter Hospital
One hundred nine E. faecium blood culture and selected
screening isolates from John Hunter Hospital in New
South Wales (NSW) obtained between 2007 and 2015
were available for WGS. Of these we identified 12 ST796
isolates, all from 2015. These comprised one VSE and
one VRE from adults with positive blood cultures, and
ten screening isolates from a NICU colonization
outbreak.
Monash Health
A large outbreak of VRE colonization in the NICU
and special care nurseries at Monash Health in
Melbourne was recognized in October 2013, with
VRE never previously detected in these wards [17].
WGS was performed on 26 isolates (two environmen-
tal swab isolates, one urine culture, one eye swab,
one blood culture and 21 screening samples from
more than 40 colonized neonates).
Royal Adelaide Hospital
Two of five patient isolates from a VRE colonization out-
break in September 2013 at the Royal Adelaide Hospital
in South Australia matched the SNP HRM type of
ST796 so were included in WGS analysis.
WGS and bioinformatic analyses
Short read sequencing libraries were generated from
genomic DNA using the Illumina Nextera XT DNA
sample preparation kit. Libraries were sequenced on the
Illumina platform using either the MiSeq with 250-cycle
paired end chemistry or the NextSeq 500 with 150-cycle
paired end chemistry according to the manufacturer’s
instructions.
Snippy v3.2 (https://github.com/tseemann/snippy) was
used to map sequence reads against the fully assembled
Ef_aus0233 genome (GenBank accession no. PRJEB14733),
a representative of the ST796 lineage [22]. Single nucleo-
tide polymorphisms (SNPs) in core genome positions were
used to construct a Maximum Likelihood tree with
Fig. 1 Source of 131 ST796 E. faecium isolates from seven hospitals across Australia and New Zealand
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FastTree v2.1.8 [23]. The tree was used as a guide for Clo-
nalFrame v1.7 to infer regions of recombination [24]. As
previously described, a robust and recombination-free tree
was generated [22]. Tree branches with less than 70% boot-
strap support (500 replicates) were collapsed. Pairwise core
non-recombinogenic SNP differences between isolates
were tabulated and visualized using a custom R-script
(https://github.com/MDU-PHL/pairwise_snp_differences).
Ethics approval
VRE isolates were collected and compared, along with
rates of BSI, using non-identifying data as part of standard
infection control procedures under appropriately consti-
tuted infection control committees at each institution.
Results
Bacteremia at Austin Health
To better understand the changing epidemiology of E.
faecium BSI at Austin Health, we plotted the rates at
six-month intervals between 1998 and 2014 of VRE E.
faecium BSI by ST (Fig. 2). This analysis showed the
dominance of ST203 in 2009, then ST796 emerging in
mid-2011 and becoming dominant by mid-2012. Of the
40 VSE (51% of all E. faecium BSI), nine were ampicillin-
susceptible with all of these being community-associated
infections, and none were ST796. Although ST796 and
ST203 E. faecium caused BSI in roughly equal measure
during 2012, the next 16 consecutive cases of VRE BSI
over 15 months were all vanB ST796, almost completely
replacing ST203.
Phenotypic antibiotic resistance
Forty-six ST796 blood culture isolates underwent anti-
microbial susceptibility testing (27 from Austin Health,
17 from Alfred Health, and two from John Hunter
Hospital). All were ampicillin-resistant and all except
one harboured vanB. Thirty-nine of 45 vanB isolates
(87%) tested vancomycin-resistant, but two tested
susceptible (MIC ≤4 mg/L) and four intermediate (MIC
8-16 mg/L). Thirty isolates (65%) had high-level genta-
micin resistance. Two (4%) had intermediate susceptibil-
ity to linezolid (with none of the known 23S rRNA
mutations or optrA genes; data not shown). All were
susceptible to teicoplanin.
Additional testing of the Austin Health isolates
revealed one with high-level streptomycin resistance, but
no resistance to tigecycline, quinupristin-dalfopristin or
chloramphenicol. All isolates were susceptible to dapto-
mycin (although most had MICs of 3-4 mg/L). The
ST796 isolates did not have additional antibiotic resist-
ance or higher MICs than the ST203 clones they
replaced (data not shown).
Phylogenomics
The core genomes of 131 ST796 isolates were compared.
SNPs were identified between these genomes and used
to create a maximum likelihood phylogenomic tree
(Fig. 3). To focus on the clonal heritage of the isolates,
SNPs within regions of recombination (411 and 1895
clonal and recombinogenic core SNPs, respectively) were
omitted from the sequence alignment that was used for
tree building (Fig. 3).
The 128 vanB isolates formed a cohesive and mono-
phyletic phylogroup (9.5 mean core SNPs) while the sin-
gle vanA and two VSE ST796 isolates formed distinct
phylogroups (20 core SNPs between the VSE isolates).
The VSE phylogroup was furthest from the ST796 Most
Recent Common Ancestor (MRCA) and was separated
from the vanA and vanB phylogroups by 89 and 123
mean core SNPs, respectively. The single vanA isolate
was separated from the VSE and vanB phylogroups by
89 and 61 mean core SNPs, respectively and was phylo-
genomically further from the ST796 MRCA than that of
the vanB phylogroup.
The basal position of the vanB to that of the VSE
isolates suggests that these isolates may have lost vanB.
This feature of ST796 population structure was also ob-
served in an accompanying study that focused on the
genomic evolution of this emerging clone [22]. Similarly,
this would also imply that the vanA isolate may have
evolved from an ST796 progenitor that was originally
vanB. One ST796 isolate with both vanA and vanB
genotypes was identified; interestingly, this isolate
clustered tightly within the vanB phylogroup, suggesting
that it was originally harbouring vanB then horizontally
acquired the vanA plasmid.
Despite the limited core SNP diversity observed
among the vanB isolates, the existence of signature SNPs
was linked to an isolate’s institution of origin. For some
vanB isolates from a common institution there was
Fig. 2 Rates of VRE E. faecium bacteremia by ST over 17 years at Austin
Health, Melbourne. We have observed two recent outbreaks of VRE
bacteremia, the first with ST203 which has now been almost
completely replaced by ST796. *One isolate from 2010 was not typed
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sufficient core SNP identity to group them on a single
node. The existence of isolates with identical core SNPs
is indicative of sustained intra-institution circulation,
where the founding bacteria have undergone a popula-
tion bottleneck and consequently developed conserved
alleles that are institution-specific. Despite such group-
ings, other vanB isolates formed singleton branches that
radiate outward from the vanB MRCA. The singleton
branches likely represent rapid evolutionary radiations
from the vanB MRCA – a hallmark of a recently
emerged and rapidly disseminated clone.
To examine the relationship between the number of
core SNP differences and the originating institutions, a
pairwise core SNP comparison was undertaken (Fig. 4).
The expectation for a clonal population is low intra-
group diversity and higher inter-group diversity. Here,
discrepancies between the intra-group and inter-group
comparisons for all institutions were very modest and in
some cases non-existent, indicating they do not contain
single ST796 genotypes but rather multiple genotypes.
Such substantial intra-institution diversity is consistent
with a scenario of multiple inter-hospital transmission
events.
Discussion
E. faecium ST796 was first recognised at Austin Health
at the beginning of 2012 and by 2014 had completely
replaced the predecessor ST203 as a cause of BSI at that
institution. This was not due to additional antibiotic
resistance so the apparent enhanced fitness of ST796 is
likely due to an alternative survival advantage. ST796
appeared almost simultaneously in two hospitals in
Auckland New Zealand in 2012, and by 2015 had reached
Newcastle, NSW. Using WGS to investigate this outbreak
(See figure on previous page.)
Fig. 3 Maximum likelihood phylogenomic tree of 131 ST796 isolates. The tree was constructed from non-recombinogenic core SNPs and branches
with less than 70% bootstrap support (500 replicates) were collapsed. The VSE, vanA and vanB isolates formed distinct and robust phylogroups. The
single vanA + vanB isolate clustered within the vanB phylogroup. Branch lengths are proportional to core SNP differences with the scale as indicated.
The inferred occurrences of intra-hospital evolution among the vanB isolates are labelled (brackets). The phylogenomic position of the ST796 most
recent common ancestor (MRCA) in the ST796 tree was identified by using Enterococcus hirae (hirae_ATCC_9790, GenBank accession no. CP003504) as
an outgroup. A = Alfred Health, Melbourne; B = Auckland City Hospital; C = Austin Health, Melbourne; D = John Hunter Hospital, Newcastle; E = other
Auckland hospital; F = Monash Health, Melbourne; G = Royal Adelaide Hospital
Fig. 4 Pairwise comparisons of non-recombinogenic core SNP differences according to institution of origin. Overall, intra-hospital diversity is equal
to or greater than inter-hospital diversity, indicating that there is substantial ST genomic admixture within each hospital. Comparisons are ordered
according to increasing means. A = Alfred Health, Melbourne; B = Auckland City Hospital; C = Austin Health, Melbourne; D = John Hunter Hospital,
Newcastle; E = other Auckland hospital; F = Monash Health, Melbourne; G = Royal Adelaide Hospital
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we observed genomic signals that were indicative of both
rapid inter-hospital transmission and in some cases,
sustained secondary intra-institution circulation. Our
observation of a surge in BSI at Austin Health due to the
appearance of ST796 is supported by results from
Australian national surveys of E. faecium BSI from
the Australian Group on Antimicrobial Resistance
(AGAR). In the 2010 survey, ST796 was not detected,
however in 2014, ST796 was responsible for 66% of
BSI isolates in Victorian hospitals, 14% in Tasmania and
4% in South Australia [18, 25, 26]. Notably ST796 was not
detected in other Australian states, even though we
now know it had reached John Hunter Hospital in
NSW as a colonizing and infecting strain. This very
rapid spread within Victoria indicates high transmissi-
bility of ST796, but may also reflect different infec-
tion control procedures at the time of inter-hospital
transfer or greater mixing of patients between institu-
tions compared with other states. Similarly, a recent
Victorian outbreak of carbapenem-resistant Enterobac-
teriaceae is now understood to be linked to admission
or transfer from a single center [27].
In addition to BSI, ST796 E. faecium also caused rapid,
clinically silent outbreaks of colonization in several loca-
tions: two hospitals in New Zealand, NICUs at Monash
Health, and John Hunter Hospital, more than 800 km
away. It is likely that undetected transfer of VRE between
patients preceded the sharp rise in BSI in Victoria. In New
Zealand, ST796 colonization was shown to be linked to
international transfer of patients from hospitals in
Victoria. We did not identify epidemiological links be-
tween other Melbourne hospitals and those where ST796
was identified in South Australia or NSW. However it
seems likely that ST796 was disseminated in a similar
manner, carried by undetected colonized patients.
All vanB ST796 isolates we assessed are very closely
related at the core genome level, irrespective of the loca-
tion or date of isolation over three years. In contrast,
significant differences in relationship were observed
between the two ST796 VSE isolates and the ST796
vanA isolate when compared to their ST796 vanB
counterparts (including the single vanA and vanB ST796
isolate). These differences are not explained by the
presence or absence of different vancomycin resistance
elements as these are excluded when determining core
genome. Furthermore, all but one of the ST796 E.
faecium isolated from blood cultures were vanco-
mycin-resistant. This contrasts markedly with the pre-
vious ST203 outbreak at Austin Health and other
mainland Australian states in which ST203 isolates
were frequently clonally diverse and included VSE
and VRE isolates [19], and with the complexity and
diversity of hospital outbreak strains in a single cen-
ter from Sydney [28].
This report has a number of limitations. Firstly, it is an
observational study, with VRE screening not standard-
ized across the institutions. Secondly, WGS was not per-
formed on all new rectal colonization VRE isolates from
the study sites due to cost, so we cannot assess the
distribution of colonizing E. faecium STs, nor calculate
the “attack rate” of ST796 from colonization to BSI.
Thirdly, we cannot explain why the population structure
of ST796 VRE has remained so clonal compared with
the much greater diversity found within the previous
ST203 outbreak strain. This suggests a survival advan-
tage in hospitals of ST796 VRE over its predecessors but
what exactly this is remains to be determined.
Cost, lack of single rooms and isolation fatigue make
VRE control for those hospitals with endemic colonization
a major challenge [21, 29]. Where VRE is not endemic,
swift recognition and enhanced infection control may still
be effective [17, 30]. Our data suggest that if we wish to
control VRE colonization and infection in hospitals that
are not yet endemic then more attention must be paid to
movements of patients and possibly staff who have had
contact with VRE-endemic hospitals.
Conclusion
In conclusion, we have tracked a novel clone of ST796
E. faecium close to the start of its existence in Victoria
Australia, where it has largely displaced ST203 as the
leading cause of VRE BSI. In contrast ST796 has not
caused significant invasive disease despite extensive
colonization in a Melbourne NICU, John Hunter Hos-
pital in NSW or in hospitals in Auckland – possibly due
to differences in patients’ underlying medical conditions.
WGS has demonstrated an essentially clonal population
structure of ST796, but unlike the multi-drug-resistant
gram-negatives, emerging healthcare-associated strains
of E. faecium do not appear to depend for their success
on enhanced antibiotic resistance. This suggests that
other determinants of clonal success drive the rapid
appearance and dissemination of new successful clones.
One possibility is resistance to biocides rather than
antibiotics per se; we are now actively investigating this
possibility [31].
Additional file
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